LivaNova Beats Q4 Earnings Estimates

The medical technology company reported higher-than-expected revenue and earnings for the quarter.

Feb. 27, 2026 at 8:11pm

Got story updates? Submit your updates here. ›

LivaNova (NASDAQ:LIVN), a global medical technology company, announced its Q4 2026 earnings results on Wednesday. The company reported earnings per share of $0.86, topping the consensus estimate of $0.80. LivaNova's revenue for the quarter came in at $360.86 million, higher than the expected $354.31 million. The company's cardiac surgery and neuromodulation businesses both saw year-over-year revenue growth.

Why it matters

LivaNova's better-than-expected financial performance signals that the company is executing well despite the challenging macroeconomic environment. As a leading provider of medical devices and therapies for cardiac surgery and neuromodulation, LivaNova's results are closely watched by investors as an indicator of broader trends in the healthcare industry.

The details

LivaNova reported a negative net margin of 17.46% but a positive return on equity of 16.54% for the quarter. The company also updated its full-year 2026 earnings guidance to $4.15-$4.25 per share. During the quarter, LivaNova saw increased demand for its products used in cardiopulmonary bypass procedures, including oxygenators, heart-lung machines, and sutureless heart valves.

  • LivaNova announced its Q4 2026 earnings results on Wednesday, February 27, 2026.
  • In the same quarter a year earlier, the company reported earnings per share of $0.81.

The players

LivaNova

A global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

What’s next

The company's full-year 2026 guidance will be closely watched by investors to gauge LivaNova's growth prospects.

The takeaway

LivaNova's strong Q4 results demonstrate the company's ability to navigate the current economic landscape and deliver value to shareholders. The company's focus on innovation in cardiac surgery and neuromodulation therapies positions it well for continued success in the healthcare industry.